Cytosorbents (CTSO) Registration Filing summary

Company overview and business model

• Specializes in blood purification technologies for critical care and cardiac surgery, using proprietary polymer adsorption technology to treat life-threatening conditions such as sepsis, trauma, and organ failure.

• Flagship product, CytoSorb, is commercialized in the EU and used globally in over 237,000 treatments; additional products and candidates target a range of medical and veterinary applications.

• Holds 21 issued U.S. patents and multiple international patents, with a broad pipeline including CytoSorb XL, DrugSorb-ATR, HemoDefend, and others.

• Focuses on expanding into U.S. and Canadian markets, growing core product sales, and maintaining tight expense control.

Financial performance and metrics

• As of July 25, 2024, public float is $59,111,703 based on 52,778,307 shares held by non-affiliates at $1.12 per share.

• Last reported sale price of common stock on Nasdaq Capital Market was $1.03 per share on July 25, 2024.

• Classified as a smaller reporting company, with less than $250 million in public float and reduced disclosure obligations.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, including funding clinical studies, supporting manufacturing, sales and marketing, repaying debt, and product development.

• The company retains broad discretion over allocation of proceeds.